Cost-effectiveness Analysis of Levofloxacin and Cefoxitin in the Treatment of Adult Non-severe Communi-ty-acquired Pneumonia / 中国药房

ABSTRACT

OBJECTIVE:To evaluate and compare cost-effectiveness of levofloxacin and cefoxitin in the treatment of adult non-severe community-acquired pneumonia(CAP). METHODS:71 cases of adult non-severe CAP were selected and divided into levofloxacin group (group A,33 cases) and cefoxitin group (group B,38 cases). Gronp A received Mesylate levofloxacin injec-tien 200 ml inotraveously,once a day;group B received Cefoxitin for injection 2.0 g intravenously,3 times a day,for 8 days. Clinical efficacy,excellence time and ADR of 2 groups were observed,and cost-effectiveness analysis was conducted. RESULTS:The total effective rate of group A and group B were 87.88% and 65.79%,and excellence time(5.53±2.56)d and(3.87±3.03)d, with statistical significance(P0.05). The total costs were 6 748.93 yuan and 8 110.34 yuan;the cost-effectiveness ratios were 76.80 and 123.28;incremental cost-effectiveness ratio was -61.63%. Results of sensitivity analysis matched results of cost-effectiveness analysis. CONCLU-SIONSLevofloxacin save more and is economical in the treatment of adult non-severe CAP.